Millennium Pharmaceuticals Limited

Bayer Corporation

Millenium Pharmaceuticals, Inc.

Siemens Healthcare Diagnostics Gmbh

Siemens Medical Solutions Diagnostic

Todd B Sells

Stephen G Stroud

Christopher F Claiborne

Tricia J Vos

Gabriel S Weatherhead

Lloyd J Payne

Richard J Boyce

Stuart Travers

Say-Jong Law

Guohan Yang

Hartmut Schroeder

Anand Natrajan

Qingping Jiang

Zhan Shi

Stepan Vyskocil

David J Sharpe

Masaaki Hirose

Tianlin Xu

Brian Scott Freeze

Matthew Stirling

Hana Lukinsky

Ashley Sue McCarron

Brian David Warner

Thomas Horn

Ellen H Fiss

Yongbo Hu

John E Monahan

Hong Myung Lee

Donna M Ford

Christoper F Claiborne

Leo R Takaoka

Ashley Sue Mccarron

Christopher F Clairborne

The present invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides potent inhibitors of Aurora A kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

Aurora kinase inhibitors for inhibiting mitotic progression

This invention relates to compounds and methods for the treatment of cancer. In particular, the invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising the compounds, and methods of using the compounds for the treatment of cancer.

Compounds and methods for inhibiting mitotic progression

Disclosed are chemical entities which are inhibitors of Nedd8-activating enzyme (NAE), namely, the compound {(1S,2S,4R)-4-[(6-{[(1R,2S)-5-chloro-2-methoxy-2,3-dihydro-1H-inden-1-yl]amino}pyrimidin-4-yl)oxy]-2-hydroxycyclopentyl}methyl sulfamate and pharmaceutically acceptable salts thereof; solid state forms thereof; and prodrugs thereof. Also disclosed are methods of using the chemical entities to treat disorders such as cancer.

Inhibitors of NEDD8-activating enzyme

This invention provides compounds of formula IA-i-a or IB-i-a and subsets thereof: wherein Z, HY, R, R, R, G, W, n, and A and subsets thereof are as described in the specification. The compounds are inhibitors of PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Heteroaryls and uses thereof

This invention provides compounds of formula I-A or I-B: wherein HY, G, G, R, R, W, W, n, and Ring A are as described in the specification. The compounds are inhibitors of PI3K and/or mTor and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

Chemiluminescent acridinium compounds are used in homogeneous assays to determine the concentration of an analyte in a sample without strong acid or strong base treatment. The chemiluminescent acridinium compounds include acridinium esters with electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus to inhibit pseudo-base formation, or acridinium sulfonamides with or without electron donating functional groups at the C2 and/or C7 position on the acridinium nucleus.

Applications of acridinium compounds and derivatives in homogeneous assays

Growing community of inventors

Bellingham, MA, United States of America

Todd B Sells